I count 12 abstracts on GLP1s for cancer prevention at ASCO
All of them are observational, and it's clear a proper randomized trial is needed here – two things on that
1. Lilly and Novo are not currently interested in doing it (thanks to
@theglpman for helping to figure this out)
2. The first randomized trial is planned (called INSPIRE, from the ECOG-ACRIN research group) – for primary and secondary prevention of breast cancer in 11,000 overweight (non-obese) women, with a 5 year follow-up